Tohen M, Castillo J, Cole J O, Miller M G, de los Heros R, Farrer R J
Department of Psychiatry, Harvard Medical School, Belmont, Mass.
J Clin Psychiatry. 1991 Dec;52(12):496-8.
Carbamazepine is increasingly being used in the acute and maintenance treatment of patients with bipolar disorder. Thrombocytopenia represents a serious adverse effect of carbamazepine with which clinicians need to be familiar. The authors describe the course of thrombocytopenia associated with carbamazepine in four patients with bipolar disorder. In all cases, thrombocytopenia appeared 14 to 16 days after the initiation of carbamazepine; also in all cases the platelet count completely recovered within 7 days after the carbamazepine treatment was discontinued. Thrombocytopenia secondary to carbamazepine appears soon after the initiation of treatment and is rapidly followed by recovery after drug discontinuation.
卡马西平越来越多地用于双相情感障碍患者的急性和维持治疗。血小板减少是卡马西平的一种严重不良反应，临床医生需要对此有所了解。作者描述了4例双相情感障碍患者中与卡马西平相关的血小板减少病程。在所有病例中，血小板减少均出现在开始使用卡马西平后14至16天；同样在所有病例中，血小板计数在停用卡马西平治疗后7天内完全恢复。卡马西平继发的血小板减少在治疗开始后不久出现，停药后迅速恢复。
